Bal Pharma Ltd.
Snapshot View

96.80 -0.45 ▼-0.5%

23 July 2021, 04:00:00 P.M.
Volume: 4,983

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.balpharma.com
Financial Indicators
Market Cap 144.15 Cr.
Earnings per share (EPS) -2.41 Trailing Twelve Months Ending 2020-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2020-12
Industry PE 35.17 Trailing Twelve Months Ending 2020-12
Book Value / Share 38.40 Trailing Twelve Months Ending 2020-12
Price to Book Value 2.53 Calculated using Price: 97.25
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.48 Cr. 14,822,372 Shares
FaceValue 10
Company Profile

Bal Pharma, incorporated in 1987 is engaged in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.

The company exports APIs to countries like Japan, Australia, Spain, UK, Canada, Nigeria, Iceland, Slovenia, Romania, Argentina, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, Turkey, Egypt, Korea, Venezuela, Italy, Portugal, Morocco, Poland, Netherlands, Syria, Bangladesh, and Indonesia, etc.

It offers products for treatment for diabetes, cardiometabolics, gynaecology, dermatology, gastroenterology, orthopaedics, ENT and multi-speciality segments.

In India, the company operates its marketing through 5 divisions namely Multi-Specialty, Glyduz, Servetus, Bal Vedics and Zennova. It has distribution network of 1000 wholesalers that caters over 1,00,000 retailers.

The company produces range of APIs that includes Anti Histamine, Platelet inhibitor, Antidiabetic, Anti Convulsant, urinary incontinence, Neuropathic pain, Anti allergy, Anti inflammatory, Diuretic, Acne Treatment etc

Bal Pharma's R&D unit is engaged in developing processes for novel bulk actives (active pharmaceutical ingredients, APIs) and new chemical substances for therapeutic applications.

The company’s manufacturing facilities has been approved by WHO-GMP and has obtained the ISO 9001:2000 accreditations for quality management.

Businesses

  • API / Intermediates
  • Finished Formulations
  • Ayurvedic
  • Research and Development

Future Plans

Bal Pharma is planning to set up new facility in Uttaranchal, with an objective to enter into regulated markets. The company also plans to foray in the business of contract manufacturing.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.46%
1 Week
-4.82%
1 Month
-1.48%
3 Month
-6.65%
6 Month
+79.59%
1 Year
+128.57%
2 Year
+103.36%
5 Year
-4.11%
9 years 2005-03 2011-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 1.14 12.03 7.00 0.49 -0.69 0.59 3.27 -21.65
Return on Capital Employed (%) 8.51 14.05 10.88 7.35 7.59 7.45 6.88 -0.44
Return on Assets (%) 0.31 3.50 2.23 0.14 -0.18 0.15 0.83 -5.16

Balance Sheet View Details

Particulars 8 years 2011-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 36 50 55 55 62 65 67 52
Non Curr. Liab. 65 18 16 45 30 46 38 34
Curr. Liab. 35 87 92 111 143 154 163 159
Minority Int. 0 0 -2 -5 -6 -7
Equity & Liab. 135 155 164 211 233 260 261 238
Non Curr. Assets 54 60 59 68 69 75 78 77
Curr. Assets 81 95 105 143 165 185 183 161
Misc. Exp. not W/O
Total Assets 135 155 164 211 233 260 261 238

Profit Loss View Details

Particulars 8 years 2011-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 114 179 187 198 229 209 225 171
Other Income 1 1 1 1 3 2 1 2
Total Income 115 180 188 200 232 211 226 173
Total Expenditure -104 -161 -170 -183 -214 -192 -207 -166
PBIDT 11 19 18 16 18 19 19 7
Interest -7 -7 -7 -6 -8 -9 -13 -13
Depreciation -3 -5 -7 -7 -6 -7 -6 -8
Taxation -1 -2 -1 -2 -3 -3 2 1
Exceptional Items
PAT 0 5 4 0 0 0 2 -13

Cash Flow View Details

Particulars 8 years 2011-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 5 13 15 -19 6 1 8 23
Cash Fr. Inv. -2 -7 -5 -14 -8 -4 -8 -5
Cash Fr. Finan. -2 -8 -7 32 -6 4 0 -20
Net Change 1 -2 2 -1 -8 1 0 -2
Cash & Cash Eqvt 2 3 5 5 -25 3 2 1

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 42.45 42.45 42.45 42.45 42.45 42.45 42.45 44.98 44.84
Public 57.55 57.55 57.55 57.55 57.55 57.55 57.55 55.02 55.16
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 13 Jul 2021
Shareholding for the Period Ended June 30 2021
Bal Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Mon, 12 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Based on the certificate received from our R&T agents i.e TSR Darashaw Ltd we would like to confirm that the details of securities dematerialized / rematerialized during the quarter ended on 30.06.2021 have been furnished to all the stock exchanges where the equity shares of the Company are listed within the prescribed time limit.
The Share certificates received for dematerialization if any has been mutilated and cancelled after due verification and the name of the depository has been substituted in the records as registered owner within 15 days of the receipt of the certificate of security.

Mon, 12 Jul 2021
Disclosure Of Related Party Transactions.
We are submitting to the exchange the disclosure of related party transactions on consolidated basis for the half year ended 31/03/2021 which is forming part of audited accounts approved by the Board of Directors at their meeting held on 29.06.2021.

Technical Scans View Details

Fri, 23 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%